Show simple item record

dc.contributor.authorOgunrombi, Modupe Olufunmilayo
dc.date.accessioned2009-05-22T09:10:47Z
dc.date.available2009-05-22T09:10:47Z
dc.date.issued2007
dc.identifier.urihttp://hdl.handle.net/10394/1837
dc.descriptionThesis (Ph.D. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2008.
dc.description.abstractVery little is known about why and how the Parkinson's disease (PD) neurodegenerative process begins and progresses. In the course of developments for treatment of PD, the discovery of the inhibition of monoamine oxidase (MAO B) was a conceptual breakthrough, and has now been firmly established. MAO B has also been implicated in the neurodegenerative processes resulting from exposure to xenobiotic amines. For example, MAO B catalyzes the first step of the bioactivation of the parkinsonian inducing pro-neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Additional insight into the mechanism of catalysis of MAO B and the mechanism of neurotoxicity by MPTP is therefore very valuable in the pursuit of the treatment of PD.
dc.publisherNorth-West University
dc.subjectMonoamine oxidase Ben
dc.subjectMPTPen
dc.subject1-methyl-3-phenyl-3-pyrrolineen
dc.subject1-methyl-3-phenyl-3-pyrroleen
dc.subjectNeurotoxicityen
dc.subjectDopamineen
dc.subjectStriataen
dc.subjectReversible inhibitorsen
dc.subjectCompetitive inhibitionen
dc.subjectStructure-activity relationshipen
dc.titleThe synthesis and evaluation of 1-methyl-3-pyrrolines and 1-methylpyrroles as substrates and inhibitors of monoamine oxidase Ben
dc.typeThesisen
dc.description.thesistypeDoctoral


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record